Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding


Related Content

Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH
Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments
Corporate VCs Step Up Carefully to Fill VC Void
Cell-Therapy Deals A "Strategic Priority" For Shire


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts